Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Voyager TherapeuticsADMA BiologicsAxcella HealthINmune BioApplied Genetic Technologies
SymbolNASDAQ:VYGRNASDAQ:ADMANASDAQ:AXLANASDAQ:INMBNASDAQ:AGTC
Price Information
Current Price$4.56$1.65$4.25$13.62$3.99
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.71.61.61.51.5
Analysis Score4.23.53.43.53.5
Community Score2.63.02.83.33.0
Dividend Score0.00.00.00.00.0
Ownership Score1.70.81.70.80.8
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$12.23$7.80$16.13$19.25$17.58
% Upside from Price Target168.14% upside372.73% upside279.41% upside41.34% upside340.69% upside
Trade Information
Market Cap$171.70 million$200.10 million$160.18 million$203.39 million$170.58 million
Beta1.81.841.533.012.33
Average Volume500,1903,541,04279,984291,0762,941,108
Sales & Book Value
Annual Revenue$104.39 million$29.35 millionN/AN/A$2.45 million
Price / Sales1.646.82N/AN/A69.62
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.68 per share$0.44 per share$2.61 per share$2.19 per share$2.76 per share
Price / Book1.703.75N/AN/A1.45
Profitability
Net Income$-43,600,000.00$-48,280,000.00$-59,040,000.00$-7,680,000.00$-45,890,000.00
EPS($1.21)($0.92)($3.55)($0.75)($2.17)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-60.61%-166.01%N/AN/AN/A
Return on Equity (ROE)-66.46%-98.83%-79.03%-41.18%-73.06%
Return on Assets (ROA)-17.92%-37.21%-54.77%-39.34%-53.25%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.40%0.28%N/A0.17%
Current Ratio3.65%8.47%22.66%17.73%5.27%
Quick Ratio3.65%4.24%22.66%17.73%5.27%
Ownership Information
Institutional Ownership Percentage78.79%48.90%66.77%7.38%57.88%
Insider Ownership Percentage23.90%11.70%10.40%58.87%7.50%
Miscellaneous
Employees17731359483
Shares Outstanding37.65 million121.28 million37.69 million14.93 million42.75 million
Next Earnings Date5/5/2021 (Estimated)5/5/2021 (Estimated)5/10/2021 (Estimated)5/13/2021 (Estimated)5/12/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Zacks: Analysts Expect Applied Genetic Technologies Co. (NASDAQ:AGTC) to Post -$0.41 EPSZacks: Analysts Expect Applied Genetic Technologies Co. (NASDAQ:AGTC) to Post -$0.41 EPS
americanbankingnews.com - April 14 at 12:46 PM
TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy ProgramTeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
finance.yahoo.com - April 13 at 7:49 AM
Are Institutions Heavily Invested In Applied Genetic Technologies Corporations (NASDAQ:AGTC) Shares?Are Institutions Heavily Invested In Applied Genetic Technologies Corporation's (NASDAQ:AGTC) Shares?
nasdaq.com - April 7 at 5:29 PM
Applied Genetic Technologies Co. (NASDAQ:AGTC) Receives Consensus Recommendation of "Buy" from AnalystsApplied Genetic Technologies Co. (NASDAQ:AGTC) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - April 5 at 9:22 AM
AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene ConferenceAGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
finance.yahoo.com - March 31 at 12:44 PM
Is Applied Genetic Technologies Corporation (NASDAQ:AGTC), -90.73% away from high, Poised For A Strong Comeback?Is Applied Genetic Technologies Corporation (NASDAQ:AGTC), -90.73% away from high, Poised For A Strong Comeback?
marketingsentinel.com - March 25 at 8:55 AM
AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP TrialsAGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials
finance.yahoo.com - March 25 at 8:55 AM
AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
finance.yahoo.com - March 18 at 1:17 PM
AGTC to Present at Upcoming Investor ConferencesAGTC to Present at Upcoming Investor Conferences
finance.yahoo.com - March 2 at 9:10 AM
AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021
finance.yahoo.com - February 16 at 2:46 PM
AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
finance.yahoo.com - February 16 at 9:45 AM
Applied Genetic Technologies: Fiscal 2Q Earnings Snapshot | Raleigh News & ObserverApplied Genetic Technologies: Fiscal 2Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 11 at 8:51 AM
Applied Genetic Technologies Corp. to Host Earnings CallApplied Genetic Technologies Corp. to Host Earnings Call
finance.yahoo.com - February 11 at 8:51 AM
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
finance.yahoo.com - February 11 at 8:51 AM
AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards,AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards,
apnews.com - February 6 at 9:33 AM
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
finance.yahoo.com - February 4 at 9:28 AM
AGTC Announces Pricing of Public Offering of Common Stock and WarrantsAGTC Announces Pricing of Public Offering of Common Stock and Warrants
finance.yahoo.com - January 28 at 12:48 PM
AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical TrialsAGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
finance.yahoo.com - January 27 at 5:54 PM
AGTC Announces Proposed Public Offering of Common Stock and WarrantsAGTC Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - January 27 at 5:54 PM
Applied Genetic Technologies (NASDAQ:AGTC) Stock Price Has Reduced 68% In The Past Five YearsApplied Genetic Technologies' (NASDAQ:AGTC) Stock Price Has Reduced 68% In The Past Five Years
finance.yahoo.com - January 25 at 8:23 AM
Applied Genetic TechnologiesApplied Genetic Technologies
fool.com - January 22 at 9:07 PM
Applied Genetic Technologies Corp/DEApplied Genetic Technologies Corp/DE
bloomberg.com - January 22 at 9:07 PM
Global Animal Biotechnology Competitive Landscape, Technologies, Markets, 2019-2020 & 2029 Featuring 80+ Companies & 70 CollaborationsGlobal Animal Biotechnology Competitive Landscape, Technologies, Markets, 2019-2020 & 2029 Featuring 80+ Companies & 70 Collaborations
prnewswire.com - January 21 at 12:40 PM
A Novel Approach to Monitoring Freshwater HealthA Novel Approach to Monitoring Freshwater Health
technologynetworks.com - January 21 at 7:40 AM
Quantitative Food Safety Method Fishes Out the DangersQuantitative Food Safety Method Fishes Out the Dangers
technologynetworks.com - January 20 at 9:29 AM
DateCompanyBrokerageAction
3/1/2021Voyager TherapeuticsRobert W. BairdReiterated Rating
2/3/2021Voyager TherapeuticsWedbushDowngrade
2/3/2021Voyager TherapeuticsMorgan StanleyLower Price Target
2/3/2021Voyager TherapeuticsChardan CapitalLower Price Target
2/3/2021Voyager TherapeuticsBTIG ResearchDowngrade
1/25/2021Voyager TherapeuticsHC WainwrightInitiated Coverage
1/13/2021Voyager TherapeuticsCanaccord GenuityReiterated Rating
12/23/2020Voyager TherapeuticsCantor FitzgeraldDowngrade
12/23/2020Voyager TherapeuticsRaymond JamesDowngrade
11/11/2020Voyager TherapeuticsOppenheimerDowngrade
11/10/2020Voyager TherapeuticsWells Fargo & CompanyDowngrade
5/13/2020Voyager TherapeuticsNomuraReiterated Rating
3/30/2020Voyager TherapeuticsNomura SecuritiesLower Price Target
3/19/2020Voyager TherapeuticsBenchmarkInitiated Coverage
4/5/2021ADMA BiologicsJefferies Financial GroupReiterated Rating
3/26/2021ADMA BiologicsMaxim GroupReiterated Rating
8/12/2019ADMA BiologicsDawson JamesDowngrade
4/4/2019ADMA BiologicsWBB SecuritiesUpgrade
11/18/2020Axcella HealthRoth CapitalInitiated Coverage
10/26/2020Axcella HealthSVB LeerinkReiterated Rating
10/14/2020Axcella HealthJPMorgan Chase & Co.Initiated Coverage
9/25/2020Axcella HealthB. RileyInitiated Coverage
8/12/2020Axcella HealthThe Goldman Sachs GroupReiterated Rating
7/30/2020Axcella HealthPiper SandlerInitiated Coverage
3/8/2021Applied Genetic TechnologiesStifel NicolausInitiated Coverage
11/20/2020Applied Genetic TechnologiesBerenberg BankReiterated Rating
1/24/2020Applied Genetic TechnologiesJanney Montgomery ScottReiterated Rating
1/9/2020Applied Genetic TechnologiesBMO Capital MarketsBoost Price Target
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.